BEDFORD, Mass., Sept. 19, 2019 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced commercialization of the HemosIL AcuStar ADAMTS13 Activity Assay in the European Union and other ...
ADAMTS13 is a circulating zinc metalloprotease that cleaves the hemostatic glycoprotein von Willebrand factor (VWF) in a shear-dependent manner. Deficiency in ADAMTS13, owing to genetic mutations or ...
Prophylaxis With Recombinant ADAMTS13 Demonstrates Superiority vs Standard Therapy in Congenital TTP
The multinational, open-label, controlled, randomized, crossover, phase 3 TAK-755 (NCT03393975) trial demonstrated superior efficacy and safety of recombinant ADAMTS13 as prophylaxis in patients with ...
In the pregnancy reported here (the mother’s fifth pregnancy), the mother had been referred for hematology evaluation in the second trimester; at that time, fetal growth and a scan of the uterine ...
A recombinant replacement for the ADAMTS13 protein (Adzynma) missing in congenital thrombotic thrombocytopenic purpura (TTP) restored levels and reduced acute TTP events, according to interim trial ...
A consortium led by holding firm Advent and FedEx has agreed to buy InPost for 15.60 euros per share, valuing the parcel locker company at 7.8 billion euros ($9.2 billion) and aiming to further expand ...
Please provide your email address to receive an email when new articles are posted on . Mean maximum ADAMTS13 activity after recombinant ADAMTS13 exceeded 100%. Markedly fewer patients receiving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results